• Go to navigation
  • Go to content
AstraZeneca Clinical Trials

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca US

Main navigation

  • Home
  • Therapy Areas
    • Oncology/Infection
    • Cardiovascular
    • Gastrointestinal
    • Neuroscience
    • Respiratory/Inflammation
  • Drug Products
    • All Drug Products
  • Diseases & Conditions
    • All Diseases and Conditions
  • Glossary
  • Contact Us
  • Disclosure Commitment

You are here

  • Home
  • Therapy Areas
  • Neuroscience
  • An open label positron emission tomography (PET) study with (11C)flumazenil to determine central GABAA receptor occupancy of AZD6280 after oral administration to healthy volunteers.

Disease
anxiety, schizophrenia
Drug Name
AZD6280
Generic Name
AZD6280
Sponsor
AstraZeneca
Drug Status
Discontinued
Phase
I
Start Date
Feb 26, 2008
Study Name
D0850C00011
Study Id
D0850C00011
ClinicalTrials.gov ID
NCT00681746
Recruiting Status
Closed
Protocol Status
Not Available
Report
Sep 14, 2009
  • D0850C00011.pdf

Page tools

  • Print
  • Bookmark this page

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2013